An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2019
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms AFU
- Sponsors Teva Pharmaceutical Industries
- 19 Jul 2016 Results published in the Movement Disorders
- 28 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-011541-24).